OBJECTIVES: In this study, we sought to determine whether quantitative ultrasound (QUS) could detect the impact of corticosteroids on muscle in the absence of frank weakness. METHODS: QUS was performed on selected limb muscles of 20 brain tumor patients treated with dexamethasone and 30 healthy controls. Echointensity was quantified using gray scale level (GSL) analysis and compared between groups; correlation to corticosteroid exposure was also performed. RESULTS: Average 4-muscle GSL (±standard deviation) was greater in patients compared to controls (35.5 ± 5.61 arbitrary units (AU) versus 30.4 ± 4.17 AU, p = 0.001), with the greatest differences in tibialis anterior. Average muscle GSL also correlated to length of corticosteroid therapy (rho = 0.52, p = 0.01). CONCLUSIONS: These findings suggest that QUS may be able to quantify skeletal muscle alterations associated with chronic corticosteroid use. Further study of this approach is warranted. SIGNIFICANCE: The findings of this study may provide a tool to evaluate corticosteroid myopathy.
OBJECTIVES: In this study, we sought to determine whether quantitative ultrasound (QUS) could detect the impact of corticosteroids on muscle in the absence of frank weakness. METHODS: QUS was performed on selected limb muscles of 20 brain tumorpatients treated with dexamethasone and 30 healthy controls. Echointensity was quantified using gray scale level (GSL) analysis and compared between groups; correlation to corticosteroid exposure was also performed. RESULTS: Average 4-muscle GSL (±standard deviation) was greater in patients compared to controls (35.5 ± 5.61 arbitrary units (AU) versus 30.4 ± 4.17 AU, p = 0.001), with the greatest differences in tibialis anterior. Average muscle GSL also correlated to length of corticosteroid therapy (rho = 0.52, p = 0.01). CONCLUSIONS: These findings suggest that QUS may be able to quantify skeletal muscle alterations associated with chronic corticosteroid use. Further study of this approach is warranted. SIGNIFICANCE: The findings of this study may provide a tool to evaluate corticosteroid myopathy.
Authors: Craig M Zaidman; Elizabeth C Malkus; Catherine Siener; Julaine Florence; Alan Pestronk; Muhammad Al-Lozi Journal: Muscle Nerve Date: 2011-07-13 Impact factor: 3.217
Authors: Sigrid Pillen; Nens van Alfen; Eric J Sorenson; Andrea J Boon; Jim S Wu; Basil T Darras; Seward B Rutkove Journal: Neurology Date: 2011-03-08 Impact factor: 9.910
Authors: Craig M Zaidman; Anne M Connolly; Elizabeth C Malkus; Julaine M Florence; Alan Pestronk Journal: Neuromuscul Disord Date: 2010-12 Impact factor: 4.296
Authors: Emilio Filippucci; Walter Grassi; Andrea Di Matteo; Gianluca Smerilli; Edoardo Cipolletta; Fausto Salaffi; Rossella De Angelis; Marco Di Carlo Journal: Curr Rheumatol Rep Date: 2021-07-16 Impact factor: 4.592